Top

Published in:

01-02-2020 | Commentary

Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?

Author: Stephen Sonis

Published in: Supportive Care in Cancer | Issue 2/2020

Excerpt

Low-level laser therapy or photobiomodulation (PBM) has been enthusiastically embraced for its potential to treat or prevent a broad range of conditions—from snake bite (1) to cognitive dysfunction (2). Of all its potential applications, mitigation of cancer therapy-related toxicities, including oral mucositis, is potentially one of the most promising. While data supporting some PBM indications is soft, there is a substantial amount of literature to suggest that PBM may be an effective intervention for oral mucositis associated with cancer chemotherapy and radiation regimens (3). …

Silva LMG, Zamuner LF, David AC, Dos Santos SA, de Carvalho PTC, Zamuner SR (2018) Photobiomodulation therapy on bothrops snake venom-induced local pathological effects: a systematic review. Toxicon 152:23–29CrossRef

de la Torre JC (2017) Treating cognitive impairment with transcranial low-level laser therapy. J Photochem Photobiol B 168:149–155CrossRef

Zecha JA et al (2016) Low-level laser therapy/photobiomodulation in the management of chemoradiation therapy in head and neck cancer: Part 2: proposed applications and treatment protocols. Support Care Cancer 24:2793–2805CrossRef

Sonis ST, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE (2016) Could the biological robustness of low level laser therapy (photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol 54:7–14CrossRef

Gomes Henriques AC, Ginani F, Oliveira RM, Keesen TS, Galvão Barboza CA, Oliveira Rocha HA, de Castro JF, Della Coletta R, de Almeida Freitas R (2014) Low-level laser therapy promotes proliferation and invasion of squamous cell carcinoma cells. Lasers Med Sci 29:1385–1395PubMed

Bumps M et al (2018) Low-level laser therapy stimulates proliferation in head and neck squamous cell carcinoma cells. Front Oncol 8:343CrossRef

Schalch TD, Fernandes MH, Destro Rodrigues MFS, Guimarães DM, Nunes FD, Rodrigues JC, Garcia MP, Mesquita Ferrari RA, Bussadori SK, Fernandes KPS (2019) Photobiomodulation is associated with a decrease in cell viability and migration in oral squamous cell carcinoma. Lasers Med Sci 34:629–636CrossRef

Silveira FM et al (2019) Examining tumor modulating effects of photobiomodulation therapy on head and neck squamous cell carcinomas. Photochem Photobiol Sci In press

Blakaj A, Bonomi M, Gamez ME et al (2019) Oral mucositis in head and neck cancer: evidence-based management and review of clinical trial data. Oral Oncol 95:29–34CrossRef

10.

Gill S, Sargent D (2006) End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? The Oncologist 11:624–629CrossRef

11.

Bucci MK et al (2005) Advances in radiation therapy: conventional to 3D, to IMRT, to 4D and beyond. CA Cancer J Clin 55:117–134CrossRef

12.

Antunes HS et al (2017) Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. Oral Oncol 71:11–15CrossRef

13.

Genot-Klastersky MT et al (2019 Sep 9) Retrospective evaluation of the safety of low-level therapy/photobiomodulation in patients with head/neck cancer. Support Care Cancer. https://doi.org/10.1007/s00520

14.

Aung KL and Siu LL. Genomically personalized therapy in head and neck cancer. Cancers Head Neck 2016.

15.

Mroz EA et al (2015) Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med:e1001786

16.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR (2019) Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med 216:419–427CrossRef

Title: Could the impact of photobiomodulation on tumor response to radiation be effected by tumor heterogeneity?
Author: Stephen Sonis
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05146-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2020

Aerobic exercise during chemotherapy infusion for cancer treatment: a novel randomised crossover safety and feasibility trial

Hope-related goal cognitions and daily experiences of fatigue, pain, and functional concern among lung cancer patients

Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study

Lung cancer and family-centered concerns

Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia

Using experience-based co-design to improve the pre-treatment care pathway for people diagnosed with head and neck cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer